GLP-1 Peptide Atlas, by Delfa

CompletedPhase 1

A Trial Investigating the Effect of Oral Semaglutide on the Pharmacokinetics of Furosemide and Rosuvastatin in Healthy Subjects

A Trial Investigating the Effect of Oral Semaglutide on the Pharmacokinetics of Furosemide and Rosuvastatin in Healthy Subjects.

Lead sponsor

Novo Nordisk A/S

Asset

Semaglutide

Oral · GLP-1 agonist

Listed sites

Recruiting sites

—

Enrollment

actual

Study population

Healthy volunteers

Key I/E criteria

•BMI 20-29.9•Healthy volunteers

Primary endpoints

•AUC of furosemide•AUC of rosuvastatin

Footprint

Where this trial recruits

Site locations as reported to ClinicalTrials.gov. Site count is not enrollment count; per-site enrollment is not available from source.

Identifiers

Registered as

NCT IDNCT03010475

Org study IDNN9924-4250

Secondary ID2015-003908-23

Secondary IDU1111-1173-8618UTN

Timeline

Milestones

Study first posted2017-01-05estimated

Study start2017-01-05actual

Primary completion2017-06-04actual

Study completion2017-08-09actual

Last update posted2017-12-20actual

Assets

Investigational agents

Semaglutide

Study populations

Who this study enrolls

Healthy volunteers

Eligibility

Who can enroll

Minimum age18 Years

Maximum age65 Years

SexAll

Healthy volunteersAccepted

Inclusion criteria

•Informed consent obtained before any trial-related activities. Trial-related activities are any procedures that are carried out as part of the trial, including activities to determine suitability for the trial

•Male or female, aged 18-65 years (both inclusive) at the time of signing informed consent

•Body mass index (BMI) between 20.0-29.9 kg/m^2 (both inclusive)

•Considered to be generally healthy based on the medical history, physical examination, and the results of vital signs, electrocardiography and clinical laboratory tests performed during the screening visit, as judged by the investigator

Exclusion criteria

•Smoker (defined as a subject who is smoking at least one cigarette or the equivalent per day)

•Any blood draw in excess of 25 mL in the past month, or donation of blood or plasma in excess of 400 mL within the 3 months preceding screening

•History of major surgical procedures involving the stomach potentially affecting absorption of trial product (e.g. subtotal and total gastrectomy, sleeve gastrectomy, gastric bypass surgery)

•Have personal or family history of myopathy

•Previous history of muscular toxicity with another HMG-CoA reductase inhibitor or fibrate

•Thyroid-Stimulating Hormone outside lower limit of normal minus 10 percent and upper limit of normal plus 10 percent

•Creatine kinase above 5 x upper limit of normal

•Asian subject

Endpoints (4)

What's being measured

Protocol endpoints and posted registry outcome measures, grouped into outcome categories. Composite endpoints show their component event types. Standard codes (LOINC, SNOMED CT) are shown where available.

Safety / tolerability / PK

4 endpoints

Primary/protocol endpoint

Area under the furosemide plasma concentration-time curve

Time frame:day 1, day 7, day 54

AUC₀–∞

concentration, descriptive

Primary/protocol endpoint

Area under the rosuvastatin plasma concentration-time curve

Time frame:day 2, day 8, day 55

AUC₀–∞

concentration, descriptive

Secondary/protocol endpoint

Maximum observed furosemide plasma concentration

Time frame:day 1, day 7, day 54

Cmax

concentration, descriptive

Secondary/protocol endpoint

Maximum observed rosuvastatin plasma concentration

Time frame:day 2, day 8, day 55

Cmax

concentration, descriptive

Publications (1)

Bibliography

Records linked to this trial through ClinicalTrials.gov references, PubMed NCT search, and curated study seeds. 'Canonical' marks design/result papers; others are registry references or candidates.

Registry references + supporting bibliography

Effect of Oral Semaglutide on the Pharmacokinetics of Levonorgestrel and Ethinylestradiol in Healthy Postmenopausal Women and Furosemide and Rosuvastatin in Healthy Subjects.
Clinical pharmacokinetics2021 Sep (month)PMID33782832doi:10.1007/s40262-020-00976-xvia clinicaltrials gov reference derived + pubmed nct search

Provenance

Sources

Trial identity, design, statusClinicalTrials.gov API v2

Snapshot dateJuly 1, 2026

Endpoint classificationDelfa endpoint taxonomy v2 (May 13, 2026)

Results tableno registry results posted yet

Trial facts come from public ClinicalTrials.gov records. Endpoint categories are Delfa's classification of those records, not a ClinicalTrials.gov field. All figures reflect the July 1, 2026 snapshot.